Paxmedica comments on common stock volatility

Engages shareintel to track market activity tarrytown, ny, june 22, 2023 (globe newswire) -- via newmediawire -- paxmedica, inc. (nasdaq: pxmd), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (apt) for the treatment of autism spectrum disorder (asd) and other serious conditions with intractable neurologic symptoms, today announced that the management and board of directors of paxmedica are aware of the recent market volatility in the company's common stock.  paxmedica is not aware of any news that might be relevant to the recent share price fluctuations, however management takes its fiduciary responsibility very seriously, and have engaged the services of shareholder intelligence services llc (“shareintel”) to better understand the investor base and the trading behavior around the company's securities.
PXMD Ratings Summary
PXMD Quant Ranking